HUTCHMED (China) Limited (HCM) News
Follow HUTCHMED (China) Limited (HCM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
HUTCHMED’s ORPATHYS and TAGRISSO Accepted for Regulatory Review
HUTCHMED said filings for ORPATHYS and AstraZeneca’s TAGRISSO were accepted for regulatory review in Europe and Japan.
EQUITY | Nov 02, 2026, 10:08 AM UTC
L
Hutchmed, AstraZeneca Say Treatment Reduces Lung Cancer Disease Progression
The companies said their Orpathys plus Tagrisso treatment reduced disease progression in metastatic non-small cell lung cancer.
EQUITY | Oct 26, 2026, 09:32 AM UTC
H
HCM - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
HCM - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
GEOPOLITICS | Sep 24, 2026, 12:00 AM UTC
H
HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript
HUTCHMED (China) (NASDAQ: HCM ) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire
LIVE | Sep 18, 2026, 07:54 AM UTC
L
Hutchmed announces licensing agreement with GSK for KRAS-EGFR therapy
Hutchmed said it has announced a licensing agreement with GSK for a KRAS-EGFR antibody conjugate cancer therapy.
EQUITY | Sep 03, 2026, 04:00 AM UTC
L
Hutchmed says SANOVO trial shows PFS benefit with ORPATHYS+TAGRISSO in China
Hutchmed said its SANOVO trial showed a progression-free survival benefit for ORPATHYS plus TAGRISSO in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China.
GEOPOLITICS | Aug 31, 2026, 12:00 AM UTC
M
HUTCHMED gets NMPA approval for ATLED in FGFR2 intrahepatic cholangiocarcinoma
Hutchmed announced NMPA approval for ATLED (fanregratinib) for treating FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma patients.
EQUITY | Aug 28, 2026, 12:00 AM UTC
M
HUTCHMED’s ORPATHYS plus TAGRISSO shows OS and PFS gains after TAGRISSO progression
HUTCHMED (HCM) says ORPATHYS® plus TAGRISSO® demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression
EQUITY | Aug 17, 2026, 12:00 AM UTC
L
HCM - HUTCHMED Reports 2026 Interim Results
HCM - HUTCHMED Reports 2026 Interim Results
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
HUTCHMED Says China Grants Conditional Approval For ORPATHYS In MET-Amplified Gastric And Gastroesophageal Junction Cancer
HUTCHMED Says China Grants Conditional Approval For ORPATHYS In MET-Amplified Gastric And Gastroesophageal Junction Cancer
GEOPOLITICS | Jul 02, 2026, 08:46 AM UTC
M
HCM Presents Fanregratinib Data
HUTCHMED presents pivotal phase II data for fanregratinib in intrahepatic cholangiocarcinoma at ESMO Gastrointestinal Cancers Congress 2026
EQUITY | Jun 25, 2026, 12:30 AM UTC